PHVS
Pharvaris BVNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$2.07B
P/E Ratio
—
EPS
$-3.16
Beta
-2.33
52W High
$33.33
52W Low
$15.46
50-Day MA
$28.55
200-Day MA
$25.66
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Pharvaris BV
Pharvaris NV, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of rare disease therapies. The company is headquartered in Leiden, the Netherlands.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-171.77M |
| Operating Margin | 0.00% |
| Return on Equity | -73.00% |
| Return on Assets | -42.30% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $4.88 |
| Price-to-Book | 7.55 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -1.38 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $69.88M |
| Float | $40.09M |
| % Insiders | 6.16% |
| % Institutions | 85.16% |
Historical Volatility
HV 10-Day
64.76%
HV 20-Day
55.59%
HV 30-Day
58.20%
HV 60-Day
51.85%
HV Rank
58.7%
Volatility is currently expanding
Analyst Ratings
Consensus ($46.51 target)
3
Strong Buy9
Buy1
HoldMore HEALTHCARE Stocks
Data last updated: 5/25/2026